Briciclib

• Description :

  Briciclib (ON 014185) is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib can be used for the study of hematological system tumors and solid tumors[1].

• Product Name Alternative :

  ON 014185

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; Caspase; CDK; c-Myc; Eukaryotic Initiation Factor (eIF) ; MDM-2/p53

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Briciclib.html

• Concentration :

  10mM

• Purity :

  99.45

• Solubility :

  DMSO : ≥ 31 mg/mL

• Smiles :

  O=S(CC1=CC(OP(O)(O)=O)=C(OC)C=C1)(/C=C/C2=C(OC)C=C(OC)C=C2OC)=O

• Molecular Formula :

  C19H23O10PS

• Molecular Weight :

  474.42

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Neel Jasani, et al. Abstract 1649: Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent. Cancer Research. August 2015, Volume 75, Issue 15.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  EIF4

• CAS Number :

  [865783-99-9]